Loading clinical trials...

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE1

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects

NCT06774313•AbbVie

View on ClinicalTrials.gov

Summary

This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•All Parts:
•Volunteers in general good health.
•Part 3, ONLY:
•HAN CHINESE Participants:
•Participant must be first- or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health.
•First-generation participants will have been born in China to two parents and four grandparents, who were also born in China, and are of full Chinese descent.
•Second-generation participants born outside of China must have two parents and four grandparents born in China and are of full Chinese descent.
•OR
•JAPANESE Participants:
•Participant must be first- or second-generation Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health.
+2 more criteria

Exclusion Criteria

•History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
•Use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.
•History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.

Locations (1)

Acpru /Id# 271899

Grayslake, Illinois, United States

Key Dates

Start Date

January 22, 2025

Primary Completion Date

April 1, 2026

Completion Date

April 1, 2026

Last Updated

February 17, 2026

Enrollment

ACTUAL participants

Conditions

Healthy Volunteer

Interventions

ABBV-142

DRUG

ABBV-142

DRUG

Placebo

DRUG

Placebo

DRUG

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

Inclusion Criteria

Exclusion Criteria

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

A Study of ENX-104 in Healthy Participants

Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle